Igyxos
Igyxos Biotherapeutics develops monoclonal antibodies designed to treat male and female infertility by boosting the activity of Follicle Stimulating Hormone (FSH). The company's lead clinical candidate, IGX12, aims to improve the efficacy and potency of existing reproductive treatments. Their target market includes the estimated 186 million individuals globally affected by reproductive system diseases.
Visit websiteNouzilly, France
Biotechnology
Healthcare
Reproductive Health
Funding summary
- Total raised
- €7.5M
- Funding rounds
- 1
Investors in Igyxos
Investors on record for Igyxos. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Igyxos?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors